FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025442757> ?p ?o ?g. }

• W2025442757 endingPage "198" @default.
• W2025442757 startingPage "191" @default.
• W2025442757 abstract "This is a retrospective analysis of 150 patients with advanced non-small cell lung cancer who had failed prior treatment or were unfit for chemotherapy and were treated with oral gefitinib (‘Iressa’, ZD1839; AstraZeneca) 250 mg/day. Thirty-two patients who received gefitinib for 3 weeks or less were not included in the analysis. For the remaining 118 evaluable patients, the mean age was 63.1 years; most patients had received prior chemotherapy (97.5%), Eastern Cooperative Oncology Group performance status scores 0–2 (97.4%) and stage IV disease (64.4%). The majority were symptomatic (84.6%). Disease control was observed in 30 patients (25.4%), of whom five had a partial response and 25 had stable disease; 18 (15.3%) were not evaluable. Median duration of treatment was 29.9 weeks in responding patients and 11.5 in patients with progressive disease (p<0.0001). Median overall survival was 7.3 months (15.2 months for disease control) and median progression-free survival was 3.2 months. Gefitinib was well tolerated, with grade 3/4 skin rash and diarrhea seen in 2.5 and 4.2% of patients, respectively. Clinical benefit was evaluated using questionnaires before and following treatment with gefitinib. In 82 patients with completed questionnaires, evaluation revealed symptom improvement in 40.1% and improvement in general feeling in 31.4%. Epidermal growth factor receptor (EGFR) analysis found that efficacy did not correlate with tumor EGFR overexpression. Therefore, in this retrospective analysis, gefitinib treatment provided disease control in 25% of patients who derived significant palliative benefit." @default.
• W2025442757 created "2016-06-24" @default.
• W2025442757 creator A5010017616 @default.
• W2025442757 creator A5013680239 @default.
• W2025442757 creator A5015293112 @default.
• W2025442757 creator A5017873908 @default.
• W2025442757 creator A5031587640 @default.
• W2025442757 creator A5032290149 @default.
• W2025442757 creator A5033573338 @default.
• W2025442757 creator A5035575111 @default.
• W2025442757 creator A5041575636 @default.
• W2025442757 creator A5047149449 @default.
• W2025442757 creator A5047316736 @default.
• W2025442757 creator A5048322584 @default.
• W2025442757 creator A5067076091 @default.
• W2025442757 creator A5072722289 @default.
• W2025442757 creator A5087946328 @default.
• W2025442757 creator A5090216312 @default.
• W2025442757 date "2005-02-01" @default.
• W2025442757 modified "2023-10-18" @default.
• W2025442757 title "Treatment of non-small cell lung cancer with gefitinib (???Iressa???, ZD1839): the Greek experience with a compassionate-use program" @default.
• W2025442757 cites W1839238860 @default.
• W2025442757 cites W1931508686 @default.
• W2025442757 cites W1982492706 @default.
• W2025442757 cites W2031059868 @default.
• W2025442757 cites W2070367561 @default.
• W2025442757 cites W2088280058 @default.
• W2025442757 cites W2120718661 @default.
• W2025442757 cites W2124054226 @default.
• W2025442757 cites W2129274454 @default.
• W2025442757 cites W2130652363 @default.
• W2025442757 cites W2139377071 @default.
• W2025442757 cites W2146404049 @default.
• W2025442757 cites W2159816656 @default.
• W2025442757 cites W2256815491 @default.
• W2025442757 cites W4246018859 @default.
• W2025442757 doi "https://doi.org/10.1097/00001813-200502000-00011" @default.
• W2025442757 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15655417" @default.
• W2025442757 hasPublicationYear "2005" @default.
• W2025442757 type Work @default.
• W2025442757 sameAs 2025442757 @default.
• W2025442757 citedByCount "9" @default.
• W2025442757 countsByYear W20254427572012 @default.
• W2025442757 countsByYear W20254427572014 @default.
• W2025442757 countsByYear W20254427572019 @default.
• W2025442757 crossrefType "journal-article" @default.
• W2025442757 hasAuthorship W2025442757A5010017616 @default.
• W2025442757 hasAuthorship W2025442757A5013680239 @default.
• W2025442757 hasAuthorship W2025442757A5015293112 @default.
• W2025442757 hasAuthorship W2025442757A5017873908 @default.
• W2025442757 hasAuthorship W2025442757A5031587640 @default.
• W2025442757 hasAuthorship W2025442757A5032290149 @default.
• W2025442757 hasAuthorship W2025442757A5033573338 @default.
• W2025442757 hasAuthorship W2025442757A5035575111 @default.
• W2025442757 hasAuthorship W2025442757A5041575636 @default.
• W2025442757 hasAuthorship W2025442757A5047149449 @default.
• W2025442757 hasAuthorship W2025442757A5047316736 @default.
• W2025442757 hasAuthorship W2025442757A5048322584 @default.
• W2025442757 hasAuthorship W2025442757A5067076091 @default.
• W2025442757 hasAuthorship W2025442757A5072722289 @default.
• W2025442757 hasAuthorship W2025442757A5087946328 @default.
• W2025442757 hasAuthorship W2025442757A5090216312 @default.
• W2025442757 hasConcept C121608353 @default.
• W2025442757 hasConcept C126322002 @default.
• W2025442757 hasConcept C141071460 @default.
• W2025442757 hasConcept C143998085 @default.
• W2025442757 hasConcept C167135981 @default.
• W2025442757 hasConcept C2775832928 @default.
• W2025442757 hasConcept C2776256026 @default.
• W2025442757 hasConcept C2776694085 @default.
• W2025442757 hasConcept C2776907518 @default.
• W2025442757 hasConcept C2778570526 @default.
• W2025442757 hasConcept C2778822529 @default.
• W2025442757 hasConcept C2779438470 @default.
• W2025442757 hasConcept C2780580887 @default.
• W2025442757 hasConcept C71924100 @default.
• W2025442757 hasConcept C90924648 @default.
• W2025442757 hasConceptScore W2025442757C121608353 @default.
• W2025442757 hasConceptScore W2025442757C126322002 @default.
• W2025442757 hasConceptScore W2025442757C141071460 @default.
• W2025442757 hasConceptScore W2025442757C143998085 @default.
• W2025442757 hasConceptScore W2025442757C167135981 @default.
• W2025442757 hasConceptScore W2025442757C2775832928 @default.
• W2025442757 hasConceptScore W2025442757C2776256026 @default.
• W2025442757 hasConceptScore W2025442757C2776694085 @default.
• W2025442757 hasConceptScore W2025442757C2776907518 @default.
• W2025442757 hasConceptScore W2025442757C2778570526 @default.
• W2025442757 hasConceptScore W2025442757C2778822529 @default.
• W2025442757 hasConceptScore W2025442757C2779438470 @default.
• W2025442757 hasConceptScore W2025442757C2780580887 @default.
• W2025442757 hasConceptScore W2025442757C71924100 @default.
• W2025442757 hasConceptScore W2025442757C90924648 @default.
• W2025442757 hasIssue "2" @default.
• W2025442757 hasLocation W20254427571 @default.
• W2025442757 hasLocation W20254427572 @default.
• W2025442757 hasOpenAccess W2025442757 @default.
• W2025442757 hasPrimaryLocation W20254427571 @default.
• W2025442757 hasRelatedWork W2005779868 @default.

• next